Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks

This article was originally published in The Pink Sheet Daily

Executive Summary

As analysts call for transformative M&A, executives talked up Lilly's modest diversification efforts, including its animal health business, Elanco, and strong Japanese sales.
Advertisement

Related Content

Alcresta Investment Reflects Omega Market Growth
Alcresta Investment Reflects Omega Market Growth
Servier, MacroGenics Forge Option Deal For Cancer Drug
Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs
Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode
Victoza Sales Lift Novo Nordisk 2010 Forecasts
Bydureon Goes Back To The QTc Drawing Board
Lilly To Cease Development of Phase III Alzheimer's Drug
Lilly To Cease Development of Phase III Alzheimer's Drug
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy

Topics

Advertisement
UsernamePublicRestriction

Register

PS071339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel